date/time interval
- September 1, 2022 - August 31, 2025
A phase 2 trial to evaluate safety and immunogenicity of a next-generation COVID-19 vaccine delivered by inhaled aerosol to humans
Grant
- Overview
- Affiliation
- View All
Overview
awarded by
total award amount
- CAD 6250740